Pancolitis

Ulcerative Colitis Treatment Market to Grow Exponentially by 2029- Brandessence Market Research

Retrieved on: 
Thursday, May 18, 2023
MSD, Janus, Insurance, Prevalence, Interleukin 23, Abbott Laboratories, Enzyme, Diarrhea, Colon, Protein, Acquisition, Patient, Integrin, Eli Lilly and Company, Etrolizumab, Cell adhesion, Filgotinib, GSK plc, Pancolitis, Upadacitinib, USD, FMT, HIV disease progression rates, Allergan, Safety, GSK, Risankizumab, Mirikizumab, Takeda Pharmaceutical Company, Roche, MEA, Biomarker, Abdominal pain, Ulcerative colitis, UC, AbbVie, Cancer, Antibody, Bacillota, Johnson & Johnson, Sphingosine, Colitis, Module (mathematics), IL-12, TNF, JAK, Cramp, Pfizer, Inflammation, AstraZeneca, Eli Lilly, Ozanimod, Novartis, Cytokine, Health, Pharmaceutical industry, Dietary supplement, Vaccine, Health insurance, Bayer

The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.

Key Points: 
  • The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.
  • It examines various treatment options available for ulcerative colitis, including medications, surgery, and other therapies.
  • High Cost of Treatment: One of the major challenges in the ulcerative colitis treatment market is the high cost associated with the available treatment options.
  • FMT is being explored as a potential treatment option for ulcerative colitis, with ongoing clinical trials assessing its safety and efficacy.

Ulcerative Colitis Treatment Market to Grow Exponentially by 2029- Brandessence Market Research

Retrieved on: 
Thursday, May 18, 2023
MSD, Janus, Insurance, Prevalence, Interleukin 23, Abbott Laboratories, Enzyme, Diarrhea, Colon, Protein, Acquisition, Patient, Integrin, Eli Lilly and Company, Etrolizumab, Cell adhesion, Filgotinib, GSK plc, Pancolitis, Upadacitinib, USD, FMT, HIV disease progression rates, Allergan, Safety, GSK, Risankizumab, Mirikizumab, Takeda Pharmaceutical Company, Roche, MEA, Biomarker, Abdominal pain, Ulcerative colitis, UC, AbbVie, Cancer, Antibody, Bacillota, Johnson & Johnson, Sphingosine, Colitis, Module (mathematics), IL-12, TNF, JAK, Cramp, Pfizer, Inflammation, AstraZeneca, Eli Lilly, Ozanimod, Novartis, Cytokine, Health, Pharmaceutical industry, Dietary supplement, Vaccine, Health insurance, Bayer

The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.

Key Points: 
  • The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.
  • It examines various treatment options available for ulcerative colitis, including medications, surgery, and other therapies.
  • High Cost of Treatment: One of the major challenges in the ulcerative colitis treatment market is the high cost associated with the available treatment options.
  • FMT is being explored as a potential treatment option for ulcerative colitis, with ongoing clinical trials assessing its safety and efficacy.

Marler Clark Files E. coli Lawsuit against Panera in Washington Federal Court

Retrieved on: 
Thursday, May 11, 2023
Cecum, CT, IV, Nation, United States district court, Pancolitis, Emergency department, Panera Bread, Escherichia coli, Colitis, Taylor Farms, Lettuce, CDC, Dysentery, Chronic pain, Swedish Health Services, Complaint, Genetic testing, FDA, Plaintiff, Farm, Poultry farming, Chipotle

SEATTLE, May 11, 2023 /PRNewswire/ -- An E. coli lawsuit was filed on behalf of Nicholas Lowe against Panera Bread in the Federal District Court of Washington.

Key Points: 
  • SEATTLE, May 11, 2023 /PRNewswire/ -- An E. coli lawsuit was filed on behalf of Nicholas Lowe against Panera Bread in the Federal District Court of Washington.
  • Mr. Lowe is represented by Marler Clark , the Nation's Food Safety Law Firm.
  • "Health authorities need to be transparent and companies like Panera and Taylor Farms need to be held accountable," added Marler.
  • A few days later, he began to develop symptoms consistent with E. coli O121:H19 including abdominal cramps and bloody diarrhea.

First Wave BioPharma Chairman and CEO Issues Letter to Shareholders

Retrieved on: 
Friday, April 29, 2022
CD, SARS2, CEO, Exocrine pancreatic insufficiency, Gastrointestinal disease, Patient, Letter, Cell death, GLOBE, UPS, Tissue, DDW, Oxidative phosphorylation, UC, Conference, Quality of life, EPI, Inflammatory bowel disease, IBD, Pancolitis, Acquisition, BOCA, First wave, Niclosamide, Research, Ulcerative colitis, UP, NASDAQ, Apoptosis, T helper 17 cell, FW, Mitochondrion, Inflammation, Severe acute respiratory syndrome coronavirus 2, Health, Cystic fibrosis, Safety, CP, Pharmaceutical industry

BOCA RATON, Fla., April 29, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies forgastrointestinal (GI) diseases, today announced thatJames Sapirstein, Chairman, President and CEO First Wave BioPharma, has issued a Letter to Shareholders to provide an update on recent events and an outlook for the Companys clinical programs in 2022.

Key Points: 
  • BOCA RATON, Fla., April 29, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies forgastrointestinal (GI) diseases, today announced thatJames Sapirstein, Chairman, President and CEO First Wave BioPharma, has issued a Letter to Shareholders to provide an update on recent events and an outlook for the Companys clinical programs in 2022.
  • FW-COV was demonstrated to be very safe with no serious adverse events reported by the more than 150 patients who participated in the trial.
  • We are still awaiting the complete set of data for analysis, including anti-inflammatory biomarkers, abdominal discomfort changes, and medium-term safety follow-up.
  • As a result of this development and the ongoing volatility in the biotechnology sector, effective immediately, First Wave BioPharma will be initiating austerity measures to conserve capital.

First Wave BioPharma Announces Dosing of First Patient in Phase 2b Clinical Trial Evaluating Topical Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis

Retrieved on: 
Thursday, October 14, 2021
World Health Organization, Ulcerative colitis, GI, FDA, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Budesonide, University, Colon, Acquisition, Fats, Needle, Pancolitis, Cramp, Bleeding, Inflammatory Bowel Diseases, EPI, WHO, University of Rome Tor Vergata, Clinical trial, Patient, Life, Food, Company, CEO, World, UP, Security (finance), Population, IBD, Enema, FW, NASDAQ, Niclosamide, U.S. Securities and Exchange Commission, BOCA, Steroid, First wave, Constipation, Nutrient, Digestion, Weight loss, Rectum, Abdominal pain, Cystic fibrosis, Diarrhea, Inflammation, Fatigue, Exocrine pancreatic insufficiency, Safety, UPS, Pharmaceutical industry

The trial formally launches the expansion of the companys clinical development program for niclosamide into indications for inflammatory bowel diseases.

Key Points: 
  • The trial formally launches the expansion of the companys clinical development program for niclosamide into indications for inflammatory bowel diseases.
  • Patient screening is underway at clinical trial sites in Italy and will start soon in Austria and Germany.
  • First Wave BioPharma is also planning a separate clinical trial to investigate an oral formulation of niclosamide as a potential treatment for pancolitis.
  • FW-UP is a niclosamide-based, small molecule anti-inflammatory inhibitor therapy for the treatment of ulcerative proctitis (UP) and ulcerative proctosigmoiditis (UPS).

DGAP-News: Abivax treats first patient in Phase 2b/3 ABX464 Covid-19 clinical trial

Retrieved on: 
Thursday, July 2, 2020
Medical specialties, Medicine, Clinical medicine, RTT, Autoimmune diseases, Abdominal pain, Hepatology, Abivax, Ulcerative colitis, Cancer, Hepatocellular carcinoma, Pancolitis

"The treatment of the first patient in the miR-AGE trial is an important milestone for Abivax," added Philippe Pouletty, M.D., Chairman of the Board of Abivax and CEO of Truffle Capital.

Key Points: 
  • "The treatment of the first patient in the miR-AGE trial is an important milestone for Abivax," added Philippe Pouletty, M.D., Chairman of the Board of Abivax and CEO of Truffle Capital.
  • ABX464 has already demonstrated impressive efficacy in a Phase 2a trial in another severe inflammatory disease, ulcerative colitis (UC).
  • Abivax, a clinical stage biotechnology company, is mobilizing the body's natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer.
  • Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.

PredictImmune and the Crohn’s & Colitis Foundation Announce Start of Jointly-sponsored Study to Validate PredictSURE IBD™, the First Prognostic Test for IBD, in the US Market

Retrieved on: 
Thursday, November 7, 2019
Research, Medical devices, Genetics, Clinical trials, Biotechnology, Managed care, Health, Pharmaceutical, Science, Medical specialties, Medicine, Clinical medicine, Autoimmune diseases, Diarrhea, Abdominal pain, RTT, Colitis, Ulcerative colitis, Crohn's disease, Pancolitis

The PRECIOUS study is a multi-centre, observational study of patients with active Crohns disease or ulcerative colitis, who are not receiving systemic steroids, immunomodulators or biologics.

Key Points: 
  • The PRECIOUS study is a multi-centre, observational study of patients with active Crohns disease or ulcerative colitis, who are not receiving systemic steroids, immunomodulators or biologics.
  • The patients recruited by New York University/Bellevue are the first to join the study, which will continue to recruit.
  • PRECIOUS study patients will be classified at diagnosis into high-risk and low-risk cohorts using PredictImmunes PredictSURE IBD biomarker.
  • Paul Kinnon, CEO, PredictImmune commented of the study: We see our partnership with the Crohns & Colitis Foundation as a positive step for both PredictImmune and IBD patients in the US.

Applied Molecular Transport Debuts with First Patient Dosed in Phase 1b Clinical Trial of AMT-101 in Adults with Ulcerative Colitis

Retrieved on: 
Monday, September 9, 2019
Medical specialties, Medicine, Clinical medicine, Autoimmune diseases, Colitis, Abdominal pain, RTT, Gastrointestinal tract disorders, Ulcerative colitis, Inflammatory bowel disease, Gastrointestinal tract, Pancolitis

Separately, the company announced encouraging data from the ongoing Phase 1a clinical trial of AMT-101 designed to evaluate the safety and tolerability of AMT-101 in healthy adult volunteers.

Key Points: 
  • Separately, the company announced encouraging data from the ongoing Phase 1a clinical trial of AMT-101 designed to evaluate the safety and tolerability of AMT-101 in healthy adult volunteers.
  • The Phase 1a trial is being conducted at The Charit Research Organisation, a leading clinical research institution based in Berlin, Germany.
  • Both the Phase 1a and Phase 1b trials are being overseen by Robarts Clinical Trials, a global clinical contract research organization specializing in GI diseases.
  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease that affects the innermost lining of the colon and causes ulcers to form.